December 21, 2020December 21, 2020

Abivax Completes Enrollment in ABX464 Trial for Ulcerative Colitis

News, Ulcerative colitis

Abivax has completed patient enrollment, ahead of schedule and despite the COVID 19 pandemic, in its Phase 2b trial evaluating ABX464 as a treatment candidate for people with moderate-to-severe ulcerative ... Read more

March 18, 2020March 18, 2020

Data from Abivax Trial Testing ABX464 Anti-inflammatory for UC Expected by Year’s End

News

Top-line data from an international Phase 2b clinical trial evaluating ABX464, Abivax’s lead therapeutic candidate for moderate-to-severe ulcerative colitis (UC), are expected later this year, according to the company’s financial ... Read more